BridgeBio Oncology Therapeutics (BBOT) Non Operating Income (2024 - 2026)
BridgeBio Oncology Therapeutics (BBOT) posted Non Operating Income of $4.1 million for Q1 2026, down 11.67% sequentially from $4.6 million in Q4 2025, and up 276.43% YoY from $1.1 million in Q1 2025.
BridgeBio Oncology Therapeutics (BBOT) Non Operating Income (2024 - 2026) Analysis & Trends
BridgeBio Oncology Therapeutics has reported Non Operating Income for 3 years, with the latest figure at $4.1 million in Q1 2026.
- Quarterly Non Operating Income rose 276.43% year-over-year to $4.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.1 million (up 89.83% YoY) and the FY2025 annual result came in at $11.8 million, up 78.73% from the prior year.
- Non Operating Income fell to $4.1 million in Q1 2026 per BBOT's latest filing, from $4.6 million in the prior quarter.
- Over five years, Non Operating Income peaked at $4.6 million in Q4 2025 and troughed at $1.1 million in Q1 2025.
- A 3-year average of $2.7 million and a median of $2.3 million in 2024 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2025 and 2026: Non Operating Income fell 13.73% in 2025, then jumped 276.43% in 2026.
- Over 3 years, Non Operating Income stood at $2.2 million in 2024, then jumped by 110.36% to $4.6 million in 2025, then slipped by 11.67% to $4.1 million in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered $4.1 million, $4.6 million, and $4.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | BridgeBio Oncology Therapeutics | 726.38 Mn | 500.67 Mn | - | 3.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.73 Mn |
| Mar 31, 2026 | 4.07 Mn |
| Dec 31, 2025 | 4.61 Mn |
| Sep 30, 2025 | 4.42 Mn |
| Jun 30, 2025 | 2.04 Mn |
| Mar 31, 2025 | 1.08 Mn |
| Dec 31, 2024 | 2.19 Mn |
| Sep 30, 2024 | 2.34 Mn |
| Jun 30, 2024 | 2.36 Mn |
| Mar 31, 2024 | 1.17 Mn |